Rigel Pharma Awaits FDA Approval for Tavalisse, Builds Commercial Org for Drug Launch
The U.S. Food and Drug Administration is set to rule on Tavalisse (fostamatinib disodium), an oral spleen tyrosine kinase (SYK) inhibitor, for adult patients with chronic or persistent immune thrombocytopenia…